723 related articles for article (PubMed ID: 14531725)
1. Clinical pharmacokinetics of atorvastatin.
Lennernäs H
Clin Pharmacokinet; 2003; 42(13):1141-60. PubMed ID: 14531725
[TBL] [Abstract][Full Text] [Related]
2. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
3. Effect of itraconazole on the pharmacokinetics of atorvastatin.
Kantola T; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
5. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
Lau YY; Okochi H; Huang Y; Benet LZ
Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
[TBL] [Abstract][Full Text] [Related]
7. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
9. Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats.
Dong J; Yu X; Wang L; Sun YB; Chen XJ; Wang GJ
Acta Pharmacol Sin; 2008 Oct; 29(10):1247-52. PubMed ID: 18817631
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
[TBL] [Abstract][Full Text] [Related]
11. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase.
Whitfield LR; Stern RH; Sedman AJ; Abel R; Gibson DM
Eur J Drug Metab Pharmacokinet; 2000; 25(2):97-101. PubMed ID: 11112089
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of fluvastatin.
Scripture CD; Pieper JA
Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
Black AE; Sinz MW; Hayes RN; Woolf TF
Drug Metab Dispos; 1998 Aug; 26(8):755-63. PubMed ID: 9698289
[TBL] [Abstract][Full Text] [Related]
15. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
Lau YY; Huang Y; Frassetto L; Benet LZ
Clin Pharmacol Ther; 2007 Feb; 81(2):194-204. PubMed ID: 17192770
[TBL] [Abstract][Full Text] [Related]
16. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
Kosoglou T; Statkevich P; Johnson-Levonas AO; Paolini JF; Bergman AJ; Alton KB
Clin Pharmacokinet; 2005; 44(5):467-94. PubMed ID: 15871634
[TBL] [Abstract][Full Text] [Related]
18. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Dostalek M; Sam WJ; Paryani KR; Macwan JS; Gohh RY; Akhlaghi F
Clin Pharmacokinet; 2012 Sep; 51(9):591-606. PubMed ID: 22775412
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Lea AP; McTavish D
Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.
Goosen TC; Bauman JN; Davis JA; Yu C; Hurst SI; Williams JA; Loi CM
Drug Metab Dispos; 2007 Aug; 35(8):1315-24. PubMed ID: 17470524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]